Ensuring Access to Essential Drugs Act
Summary
What This Bill Does
The Ensuring Access to Essential Drugs Act changes which drugs count as applicable drugs in the Medicare Part D manufacturer discount program. It adds an exclusion for an orally administered drug that was approved through a new drug application under Food, Drug, and Cosmetic Act section 505 and that CMS has granted a narrow exception allowing reclassification as a noninnovator multiple source drug under the Medicaid drug rebate program. The practical effect is to remove a small category of reclassified oral drugs from manufacturer discount obligations that otherwise attach in Medicare Part D.
Who Benefits and How
Manufacturers of qualifying reclassified oral drugs benefit because their products would not be treated as applicable drugs for Part D manufacturer discount obligations. Pharmacies and Part D plans may benefit if excluding the drugs helps keep niche essential products available in the market. Patients relying on affected essential oral drugs may benefit if reduced discount pressure helps preserve supply or manufacturer participation. CMS benefits from a statutory rule matching a narrow Medicaid rebate reclassification exception to Part D discount treatment.
Who Bears the Burden and How
Medicare Part D beneficiaries and plans may bear higher net costs if manufacturer discounts no longer apply to the excluded drugs. The Medicare program may bear more spending exposure for covered reclassified oral drugs. CMS must identify which NDA-approved oral drugs have the narrow Medicaid noninnovator multiple-source reclassification exception. Competing drug manufacturers that remain in the discount program may view the exclusion as uneven treatment.
Key Provisions
- Excludes qualifying orally administered NDA-approved drugs from the Part D manufacturer discount program.
- Requires CMS-granted narrow Medicaid rebate reclassification as a noninnovator multiple source drug.
- Aligns Part D discount treatment with a narrow Medicaid drug rebate exception.
- Limits the exclusion to drugs meeting both the NDA approval and CMS reclassification conditions.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Excludes certain orally administered NDA-approved drugs from the Medicare Part D manufacturer discount program when CMS has granted a narrow exception allowing the drug to be reclassified as a noninnovator multiple source drug under the Medicaid drug rebate program.
Key Policy Areas
Medicare Part D, Prescription Drugs, Pharmaceuticals
Primary Purpose
Excludes certain orally administered NDA-approved drugs from the Medicare Part D manufacturer discount program when CMS has granted a narrow exception allowing the drug to be reclassified as a noninnovator multiple source drug under the Medicaid drug rebate program.
Policy Domains
Resolution provisions
Identified Gains
- Qualifying oral drug manufacturers
- Pharmacies
- Patients relying on affected essential oral drugs
- Centers for Medicare & Medicaid Services
Identified Costs
- Part D beneficiaries and plans
- Medicare program
- Centers for Medicare & Medicaid Services
- Competing drug manufacturers
Sponsors
Legislative Progress
In CommitteeMr. Garbarino (for himself, Mrs. Harshbarger, and Mr. Suozzi) introduced …
Referred to the Committee on Energy and Commerce, and in …
Introduced in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Patients relying on affected essential oral drugs
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology